Detalles de la búsqueda
1.
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
J Neurol Neurosurg Psychiatry
; 94(4): 290-299, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36522154
2.
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.
Int J Mol Sci
; 24(10)2023 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37239872
3.
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection.
J Transl Med
; 19(1): 272, 2021 06 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34174875
4.
Detection of Mycobacterium tuberculosis DNA in CD34+ peripheral blood mononuclear cells of adults with tuberculosis infection and disease.
Int J Infect Dis
; 141S: 106999, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38458427
5.
Alternative biomarkers of tuberculosis infection in patients with immune-mediated inflammatory diseases.
Front Med (Lausanne)
; 10: 1271632, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38076244
6.
Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.
Int J Infect Dis
; 130 Suppl 1: S34-S42, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944383
7.
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis.
Biomedicines
; 11(3)2023 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36979666
8.
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Vaccines (Basel)
; 11(11)2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38006015
9.
Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.
Int J Infect Dis
; 121: 24-30, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35462039
10.
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis.
Front Neurol
; 13: 881988, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35711277
11.
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave.
Front Immunol
; 13: 920227, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35967321
12.
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy.
Front Immunol
; 13: 984098, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36148228
13.
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay.
Int J Infect Dis
; 122: 841-849, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35878802
14.
Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Front Immunol
; 13: 846753, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35309297
15.
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
Int J Infect Dis
; 125: 195-208, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328289
16.
Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Neurology
; 98(5): e541-e554, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34810244
17.
Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients.
Int J Infect Dis
; 106: 338-347, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33864921
18.
Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease.
Front Immunol
; 12: 716857, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34447382
19.
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2.
Int J Infect Dis
; 113 Suppl 1: S82-S87, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33713816
20.
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
J Infect
; 82(4): 58-66, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33639176